Elicio Therapeutics (ELTX) EBT (2020 - 2026)
Elicio Therapeutics' (ELTX) quarterly EBT came in at -$22.0 million in Q1 2026, down 102.55% YoY from $862.4 million in Q1 2025, and down 139.62% on a QoQ basis from -$9.2 million in Q4 2025.
Elicio Therapeutics (ELTX) EBT (2020 - 2026) Analysis & Trends
Elicio Therapeutics (ELTX) has 7 years of EBT data on file, last reported at -$22.0 million in Q1 2026.
- Quarterly EBT fell 102.55% year-over-year to -$22.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$66.2 million (down 25.28% YoY) and the FY2025 annual result came in at -$42.8 million, up 70.52% from the prior year.
- EBT fell to -$22.0 million in Q1 2026, from -$9.2 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$6.1 million in Q4 2022 to a low of -$22.0 million in Q1 2026.
- A 5-year average of -$12.8 million and a median of -$10.9 million in 2025 frame the typical range for EBT.
- The widest YoY moves for EBT: up 83.5% in 2022, down 142.28% in 2022.
- Tracing ELTX's EBT over 5 years: stood at -$6.1 million in 2022, then sank by 61.41% to -$9.8 million in 2023, then tumbled by 31.37% to -$12.8 million in 2024, then grew by 28.48% to -$9.2 million in 2025, then sank by 139.62% to -$22.0 million in 2026.
- The last three EBT figures came in at -$22.0 million (Q1 2026), -$9.2 million (Q4 2025), and -$18.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 177.81 Mn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | -264.70 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -11.37 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 81.49 Mn |
| 10 | Elicio Therapeutics | 59.37 Mn | 35.87 Mn | - | -10.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.64 Mn |
| Mar 31, 2026 | -22.00 Mn |
| Dec 31, 2025 | -9.18 Mn |
| Sep 30, 2025 | -18.37 Mn |
| Jun 30, 2025 | -16.64 Mn |
| Mar 31, 2025 | -10.86 Mn |
| Dec 31, 2024 | -12.84 Mn |
| Sep 30, 2024 | -10.30 Mn |
| Jun 30, 2024 | -18.84 Mn |
| Mar 31, 2024 | -10.62 Mn |
| Dec 31, 2023 | -9.77 Mn |
| Sep 30, 2023 | -19.72 Mn |
| Jun 30, 2023 | -11.25 Mn |
| Mar 31, 2023 | -8.15 Mn |
| Dec 31, 2022 | -6.05 Mn |
| Sep 30, 2022 | -10.23 Mn |
| Jun 30, 2022 | -7.34 Mn |
| Mar 31, 2022 | -14.81 Mn |
| Dec 31, 2021 | 14.32 Mn |
| Sep 30, 2021 | -41.04 Mn |